You are here
New $22 Million Project Targets Deadly Viruses
BRONX, N.Y., April 4, 2019 /PRNewswire/ -- The National Institute of Allergy and Infectious Diseases (NIAID) has awarded an international consortium led by Albert Einstein College of Medicine, part of Montefiore, a five-year, $22 million grant to develop antibody-based therapies against four highly lethal viruses for which there are no approved vaccines or treatments.
The viruses are the tick-borne Crimean-Congo hemorrhagic fever virus (CCHFV) and three hantaviruses, which are spread by rodents: Andes virus (ANDV), Sin Nombre virus (SNV), and Puumula virus (PUUV). The NIAID has designated all but PUUV as Category A agents—emerging infectious diseases or pathogens that pose the highest risk to national security and public health.
The project, called the Prometheus Center for Excellence in Translational Research (Prometheus), focuses on viruses that spread from animals to people. It builds on a 2017 study involving ebolaviruses, believed to spread to people from fruit bats or primates. In addition to Einstein, the participating institutions leading the project are the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Mapp Biopharmaceutical, Inc., The University of Texas at Austin, and Adimab, LLC, a biotech company.
Building on Ebola Research
Einstein, USAMRIID, Mapp Biopharmaceutical, and Adimab scientists were part of a team that analyzed 349 natural human antibodies against ebolavirus in the blood of a survivor of the 2013-16 West African Ebola outbreak. After finding that two of the antibodies potently neutralized all six known ebolaviruses in tissue culture, the investigators developed MBP134, a cocktail of two fully human monoclonal antibodies that protected animals against all three major disease-causing ebolaviruses. (Monoclonal antibodies, or mAbs, are antibodies made by identical immune cells that are all clones of a unique parent cell.) The current leading ebola therapy, a mAb cocktail called ZMapp, is effective against only a single ebolavirus.
"Prometheus will leverage this proven approach for rapid mAb discovery and evaluation to develop prophylactics or therapeutics for two other important groups of emerging viruses with potential to cause severe disease outbreaks in humans," said Kartik Chandran, Ph.D., principal investigator on the grant and professor of microbiology & immunology and the Harold and Muriel Block Faculty Scholar in Virology at Einstein. "With our expanded group of partners, we have the capability to go from initial antibody discovery and evaluation all the way to drug development, animal studies, clinical trials, and licensing."
Einstein will serve as the lead and coordinating institution for Prometheus and also will co-lead one of the projects with John Dye, Ph.D., chief of viral immunology at USAMRIID: identifying the most promising antiviral antibodies and studying how they block the viruses from entering host cells. Other members of the Einstein team include Jonathan Lai, Ph.D., professor of biochemistry, and Johanna Daily, M.D., M.S., professor of medicine and of microbiology & immunology and an infectious disease specialist at Montefiore.
The second project will be co-led by Zachary Bornholdt, Ph.D., director of antibody discovery at Mapp Biopharmaceuticals and Jason McLellan, Ph.D., associate professor of molecular biosciences at The University of Texas at Austin. This project will focus on engineering viral antigens to be used for antibody discovery, structural studies to define the antibody epitopes (i.e., the targets to which antibodies bind), and engineering antibodies to maximize their antiviral effectiveness in animals and humans. Other Prometheus components, led by Andrew Herbert, Ph.D., senior research scientist for the Geneva Foundation at USAMRIID, and Larry Zeitlin, Ph.D., chief executive officer of Mapp Biopharmaceutical, will focus on testing the antibodies for their effectiveness in animal models and the preclinical development of lead antibodies.
Need to Combat Emerging Threats
Dr. Chandran noted that naturally occurring, fully human mAbs are an ideal technology for addressing viral threats. First, they've participated in a successful host response to a pathogen. Second, they've undergone testing to show that they recognize the target pathogen and don't target host molecules.
"Human mAbs therefore are less likely to react to normal cells and cause toxic side effects than other therapies," added Dr. Dye. "The manufacturing processes for mAbs are well-established and mAbs have proven safety profiles, which should speed their development and reduce the risk of late failures during the later drug-development phases."
"We are looking forward to expanding on our success with the MBP134 product and further leverage through the Prometheus project our multi-disciplinary collaboration to develop viable immunotherapeutic products targeting pathogenic threats to public health," said Dr. Bornholdt.
In addition to Einstein, Prometheus comprises teams from the following institutions: Geneva Foundation, Tacoma, Washington; USAMRIID, Frederick, Maryland; Mapp Biopharmaceutical, San Diego, California; The University of Texas at Austin, Austin, Texas; Adimab LLC, Lebanon, New Hampshire; University of New Mexico, Albuquerque, New Mexico; Umeå University, Sweden; Massachusetts General Hospital, Boston, Massachusetts; and Wistar Institute, Philadelphia, Pennsylvania.
About Albert Einstein College of Medicine
Albert Einstein College of Medicine is one of the nation's premier centers for research, medical education and clinical investigation. During the 2018-2019 academic year, Einstein is home to 711 M.D. students, 160 Ph.D. students, 107 students in the combined M.D./Ph.D. program, and 265 postdoctoral research fellows. The College of Medicine has more than 1,800 full-time faculty members located on the main campus and at its clinical affiliates. In 2018, Einstein received more than $172 million in awards from the National Institutes of Health (NIH). This includes the funding of major research centers at Einstein in aging, intellectual development disorders, diabetes, cancer, clinical and translational research, liver disease, and AIDS. Other areas where the College of Medicine is concentrating its efforts include developmental brain research, neuroscience, cardiac disease, and initiatives to reduce and eliminate ethnic and racial health disparities. Its partnership with Montefiore, the University Hospital and academic medical center for Einstein, advances clinical and translational research to accelerate the pace at which new discoveries become the treatments and therapies that benefit patients. Einstein runs one of the largest residency and fellowship training programs in the medical and dental professions in the United States through Montefiore and an affiliation network involving hospitals and medical centers in the Bronx, Brooklyn and on Long Island. For more information, please visit www.einstein.yu.edu, read our blog, follow us on Twitter, like us on Facebook, and view us on YouTube.
View original content to download multimedia:http://www.prnewswire.com/news-releases/new-22-million-project-targets-deadly-viruses-300824756.html
SOURCE Albert Einstein College of Medicine